STRUCTURE-BASED DEVELOPMENT OF INHIBITORS OF VIRAL ENZYMES

基于结构的病毒酶抑制剂的开发

• 批准号: 8169991
• 负责人: Katherine S Bateman
• 金额: $ 0.27万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8169991
• 关键词: Animals; Antiviral Agents; Binding; Chymase; Computer Retrieval of Information on Scientific Projects Database; DNA-Directed RNA Polymerase; Development; Enzymes; Evolution; Funding; Grant; Human; Institution; Pharmaceutical Preparations; RNA Viruses; Research; Research Personnel; Resources; Source; Structure; United States National Institutes of Health; Viral; Virus Inhibitors; Work; base; design; inhibitor/antagonist; pathogen

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Many important pathogens of humans and animals belong to the positive-sense, single-stranded RNA viruses. Enzymes such as RNA polymerase and the chymotrypsin-like proteases are absolutely required for viral replication. Therefore, these enzymes and their precursors are ideal targets for the design of antiviral drugs. We and others have determined crystal structures of a number of viral enzymes from this group, including some with bound inhibitors. This work is valuable for the understanding of viral evolution, enzymatic mechanisms and the development of anti viral drugs. We are pursuing a project to develop different and more effective inhibitors of several viral enzymes.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 人类和动物的许多重要病原体都属于正义单链RNA病毒。 RNA聚合酶和类糜蛋白酶等酶是病毒复制所必需的。因此，这些酶及其前体是设计抗病毒药物的理想靶标。我们和其他人已经确定了该组中许多病毒酶的晶体结构，包括一些带有结合抑制剂的酶。这项工作对于理解病毒进化、酶促机制和抗病毒药物的开发具有重要价值。我们正在开展一个项目，开发多种病毒酶的不同且更有效的抑制剂。